314 related articles for article (PubMed ID: 36290817)
1. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
[TBL] [Abstract][Full Text] [Related]
2. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
3. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
Michaels E; Chen N; Nanda R
Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE; Tolaney SM
J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
[TBL] [Abstract][Full Text] [Related]
5. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Heeke AL; Tan AR
Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
10. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
11. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
13. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
He R; Yuan X; Chen Z; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
[TBL] [Abstract][Full Text] [Related]
14. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
Howard FM; Villamar D; He G; Pearson AT; Nanda R
Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
18. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
19. Single peptides and combination modalities for triple negative breast cancer.
Razazan A; Behravan J
J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
